# YY2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- YY2 is a C2H2-type zinc-finger transcription factor, a paralog of YY1, which arose via retrotransposition and underwent positive selection, resulting in a distinct N-terminal regulatory domain and conserved DNA-binding domain. It exhibits context-dependent transcriptional activation or repression, regulating genes involved in cell proliferation, apoptosis, DNA damage response, pluripotency, and metabolism.
- YY2's genomic locus is on human chromosome Xp22.33, and its promoter contains a CpG island sensitive to DNA methylation, which inversely correlates with YY2 expression; promoter hypermethylation can silence YY2 in cancer. Alternative splicing generates multiple isoforms (e.g., YY2-001, YY2-002, YY2-004) with altered subcellular localization and function, notably controlled by the splicing factor PTBP1 during embryonic stem cell differentiation.
- Structurally, YY2 possesses a less intrinsically disordered N-terminal transactivation domain compared to YY1, a glycine-rich linker region susceptible to arginine methylation, and a C-terminal four C2H2 zinc-finger DNA-binding domain that recognizes the 5'-CCATNTT-3' consensus sequence. Post-translational modifications like methylation by PRMTs and phosphorylation by CK2 modulate its activity.
- YY2 is a critical regulator of the p53/p21 axis, directly activating CDKN1A (p21) and TP53 transcription in response to DNA damage, leading to cell cycle arrest. It also plays a non-redundant role in embryonic development, regulating pluripotency and differentiation, and is implicated in metabolic reprogramming (e.g., HK2, LDHA activation) and modulation of the tumor immune microenvironment (e.g., PD-L1 expression).
- Dysregulated YY2 expression is observed in multiple malignancies (esophageal, colorectal, gastric, breast cancer), correlating with prognosis and immune infiltration; it is also implicated in non-cancer pathologies like osteoporosis and neurodevelopmental disorders. Somatic mutations in cancer and germline variants are documented, though many are classified as VUS.
- YY2 can regulate viral promoters (e.g., HPV, HBV, HCMV) and is targeted for degradation by viral oncoproteins (e.g., HPV E6, Adenovirus E1A), while also participating in innate immunity by regulating type I interferon production. Therapeutic strategies include YY2 reactivation via demethylating agents and inhibition via siRNA or small molecules, with potential for synergistic effects with immunotherapy.

---

## Executive Summary & Key Metadata

The **YY2** gene (Yin Yang 2) encodes a C2H2-type zinc-finger transcription factor that functions as a paralog of the well-characterized YY1 protein. YY2 arose via retrotransposition of the YY1 mRNA early in the eutherian mammalian lineage, followed by rapid positive selection that reshaped its N-terminal regulatory domain while preserving a highly conserved C-terminal DNA-binding domain [1]. Unlike YY1, which is ubiquitously expressed and essential for cell viability, YY2 exhibits a more restricted expression pattern, prominent in embryonic stem cells (ESCs), trophoblast stem cells, and specific adult tissues [2, 3]. YY2 binds DNA sequences highly similar to the YY1 consensus (5'-CCATNTT-3'), yet *in vivo* chromatin immunoprecipitation (ChIP) studies reveal that YY2 occupies a distinct, non-overlapping set of genomic loci, indicating functional divergence beyond simple redundancy [4, 5].

YY2 functions as a context-dependent transcriptional activator or repressor, regulating genes involved in cell proliferation, apoptosis, DNA damage response, pluripotency, and metabolism [6, 7]. Its activity is modulated by post-translational modifications (PTMs), including methylation and phosphorylation, as well as by alternative splicing that generates isoforms with altered subcellular localization and function [8, 9]. Clinically, YY2 expression is dysregulated in multiple malignancies, including esophageal carcinoma, colorectal cancer, gastric cancer, and breast cancer, where it correlates with prognosis and immune infiltration [10, 11, 12, 13]. YY2 also plays a role in non-cancer pathologies, including osteoporosis and neurodevelopmental responses to prenatal cannabis exposure [14, 15].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | YY2 |
| UniProt Accession | O15391 |
| Representative PDB ID | true (homology models; no experimental full-length structure) |
| Chromosomal Locus | Human: Xp22.33 (GRCh38: X:2,500,000–2,530,000) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor (activator/repressor) |
| Key Structural Features | N-terminal acidic/glutamine-rich transactivation domain; central glycine-rich region; C-terminal four C2H2 zinc fingers |
| Disease & Pathology Associations | Esophageal carcinoma, colorectal cancer, gastric cancer, breast cancer, osteoporosis, neurodevelopmental disorders |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Evolutionary Origin

The human YY2 gene is located on the short arm of the X chromosome at cytogenetic band **Xp22.33**, a region characterized by a high density of retrotransposed genes and pseudogenes. The gene spans approximately 30 kb of genomic DNA and is transcribed from the minus strand. YY2 is a processed retrogene: it originated from a retrotransposition event involving the YY1 mRNA, which inserted into the X chromosome after the divergence of marsupials and eutherians [1]. This evolutionary history explains the absence of introns in the ancestral YY2 open reading frame (ORF), although subsequent genomic rearrangements have introduced splice variants in some lineages.

Comparative genomics reveals that YY2 has undergone **rapid, positive selection** in its N-terminal region, while the C-terminal zinc-finger array remains highly conserved across mammals [1]. This evolutionary pattern suggests that YY2 acquired novel regulatory functions distinct from YY1, likely involving new protein-protein interactions or altered subcellular dynamics.

### 1.2 Promoter Architecture and Epigenetic Regulation

The YY2 promoter lacks a canonical TATA box but contains a **CpG island** spanning the transcription start site (TSS), a feature common to housekeeping and developmentally regulated genes [1]. The promoter is bidirectionally active in some contexts, producing both sense and antisense transcripts. Key regulatory elements include:

- **GC-boxes**: Binding sites for Sp1 and related transcription factors, which drive basal promoter activity.
- **YY1/YY2 consensus sites**: Autoregulatory loops have been proposed, where YY2 or YY1 can bind its own promoter to modulate expression [1].
- **CpG methylation**: The promoter is subject to DNA methylation at CpG dinucleotides, which inversely correlates with YY2 expression. Treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivates YY2 transcription in cell lines where it is silenced [1]. This methylation-sensitive regulation is particularly relevant in cancer, where promoter hypermethylation can silence tumor-suppressive YY2 isoforms.

### 1.3 Enhancer Elements and Chromatin Architecture

High-throughput chromatin conformation capture (Hi-C) and STARR-seq analyses have identified **distal enhancer elements** that physically interact with the YY2 promoter in a cell-type-specific manner [15]. In the context of osteoporosis, an integrative analysis of enhancer activity and chromatin interaction data revealed a **YY2-condensed regulatory axis** at risk loci, where YY2 binding to enhancers modulates the expression of bone-related genes [15]. These enhancers are marked by H3K27ac and H3K4me1 histone modifications and are bound by lineage-determining transcription factors (e.g., RUNX2 in osteoblasts).

### 1.4 Alternative Splicing and Isoform Diversity

Although YY2 originated as an intronless retrogene, the human locus has acquired alternative splicing events that generate multiple mRNA isoforms. The most well-characterized isoforms include:

| **Isoform** | **Size (aa)** | **Distinct Features** | **Functional Consequence** |
|---|---|---|---|
| YY2-001 (canonical) | 372 | Full-length; nuclear localization signal (NLS) in the C-terminus | Transcriptional activator/repressor |
| YY2-002 | 341 | Lacks exon 4; truncated N-terminal domain | Reduced transactivation capacity; altered protein stability |
| YY2-003 | 298 | Retains intron 2; premature stop codon | Predicted to undergo nonsense-mediated decay (NMD) |
| YY2-004 | 405 | Extended N-terminus via alternative first exon | Enhanced nuclear import; increased DNA-binding affinity |

The **YY2-002 isoform** is of particular interest in embryonic stem cells (ESCs). Tahmasebi et al. demonstrated that a coordinated program of alternative splicing and translation controls the ratio of YY2 isoforms during ESC differentiation [8]. Specifically, the splicing factor **PTBP1** (polypyrimidine tract-binding protein 1) promotes the inclusion of a poison exon that targets YY2 mRNA for NMD in undifferentiated ESCs. Upon differentiation, PTBP1 downregulation allows full-length YY2 expression, which in turn activates differentiation-associated genes [8]. This regulatory mechanism ensures that YY2 protein levels are tightly controlled during the pluripotency-to-differentiation transition.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The human YY2 protein (UniProt O15391) is a 372-amino-acid polypeptide with a molecular weight of approximately 41 kDa. Sequence alignment with YY1 reveals ~50% overall identity, rising to >90% within the C-terminal zinc-finger domain [2]. The protein can be divided into four functional domains:

1. **N-terminal transactivation domain (aa 1–150)**: Rich in acidic residues (glutamate and aspartate) and glutamine, this domain mediates interactions with the basal transcriptional machinery, including TATA-binding protein (TBP) and TFIIB. Unlike YY1, which contains a highly disordered N-terminus, YY2's N-terminus is **less intrinsically disordered**, as demonstrated by biophysical analyses using circular dichroism and limited proteolysis [3]. This structural difference likely contributes to YY2's distinct protein-protein interaction network.

2. **Glycine-rich linker region (aa 151–200)**: A flexible hinge connecting the N-terminal regulatory domain to the DNA-binding domain. This region is susceptible to post-translational modifications, including **methylation at arginine residues** [9]. Methylation of this region by protein arginine methyltransferases (PRMTs) modulates YY2's transcriptional activity and its ability to regulate cell proliferation [9].

3. **Central domain (aa 201–260)**: Contains a putative **nuclear export signal (NES)** and a **bipartite nuclear localization signal (NLS)**. The NES is functional in certain isoforms, allowing cytoplasmic sequestration and regulation of YY2 activity by nucleocytoplasmic shuttling.

4. **C-terminal DNA-binding domain (aa 261–372)**: Comprises **four C2H2-type zinc fingers** (ZF1–ZF4), each with the canonical motif Cys-X₂₋₄-Cys-X₁₂-His-X₃₋₅-His. These fingers recognize the consensus DNA sequence **5'-CCATNTT-3'**, with ZF2 and ZF3 making base-specific contacts in the major groove and ZF1 and ZF4 stabilizing the interaction via phosphate backbone contacts [2, 5].

### 2.2 Structural Biology and 3D Conformation

To date, no experimental high-resolution crystal structure of full-length YY2 has been solved. However, the high sequence homology of the zinc-finger domain to YY1 (PDB: 1UBD) and REX1 (PDB: 6GFT) permits reliable homology modeling. The zinc-finger domain adopts a canonical **C2H2 array architecture**, where each finger folds into a ββ-α structure: two antiparallel β-strands followed by an α-helix that inserts into the DNA major groove. The four fingers are connected by short linkers (TGEKP-like sequences) that confer flexibility and allow the fingers to wrap around the DNA helix.

The N-terminal domain, in contrast, is predicted to be **largely unstructured** under physiological conditions, a feature shared with many transcription factors that undergo **folding-upon-binding** when interacting with coactivators or corepressors [3, 4]. Figiel et al. used size-exclusion chromatography and small-angle X-ray scattering (SAXS) to demonstrate that YY2's N-terminus adopts a more compact conformation than YY1's, suggesting a reduced propensity for liquid-liquid phase separation (LLPS) [3]. This biophysical distinction has functional implications: YY1 is known to form transcriptional condensates at super-enhancers, whereas YY2 may rely on more stable, stoichiometric interactions with chromatin remodelers.

### 2.3 Post-Translational Modifications and Structural Dynamics

YY2 is subject to multiple PTMs that alter its structure and function:

- **Arginine methylation**: PRMT1 and PRMT5 methylate arginine residues in the glycine-rich region (e.g., R169, R172). Methylated YY2 exhibits enhanced transcriptional repression activity, and its overexpression suppresses cell proliferation in a p53-dependent manner [9].
- **Phosphorylation**: Casein kinase II (CK2) phosphorylates serine residues in the N-terminus, modulating YY2's affinity for DNA and its interaction with 14-3-3 proteins, which can sequester YY2 in the cytoplasm.
- **Ubiquitination**: The E3 ligase MDM2 ubiquitinates YY2, targeting it for proteasomal degradation. This is particularly relevant in the p53 pathway, where YY2 and MDM2 form a regulatory loop [7].

> **Interactive 3D Protein Visualizer: Load YY2 (PDB: true)**  
> [Interactive 3D Protein Visualizer: Load YY2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15391)  
> *This tool provides a rotatable, color-coded 3D model of YY2 based on homology to YY1 (PDB: 1UBD). Zinc ions are shown as gray spheres; the four C2H2 zinc fingers are highlighted in distinct colors. Users can toggle between cartoon, surface, and electrostatic representations.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulation: Activator and Repressor Functions

YY2 is a **bifunctional transcription factor** that can activate or repress target gene expression depending on the promoter context and the availability of cofactors [6]. Genome-wide studies using ChIP-seq in trophoblast stem cells and ESCs have identified thousands of YY2 binding sites, with a significant enrichment at promoter-proximal regions [5]. Notably, YY2 binding sites only partially overlap with YY1 sites, and motif analysis reveals that YY2 preferentially binds to a **slightly extended consensus** (5'-GCCATNTT-3') compared to YY1 [4].

YY2's activator function is mediated by its N-terminal domain, which recruits **histone acetyltransferases (HATs)** such as p300/CBP and the Mediator complex. In contrast, its repressor function involves recruitment of **histone deacetylases (HDACs)** and **Polycomb repressive complex 2 (PRC2)** via interactions with EZH2 [6]. The switch between activation and repression is regulated by PTMs: methylated YY2 preferentially interacts with HDACs, while unmodified YY2 binds p300 [9].

### 3.2 The p53/p21 Axis and DNA Damage Response

A seminal study by Kasim et al. established YY2 as a **novel regulator of the p53/p21 axis** [7]. In response to DNA damage, YY2 expression is induced, and YY2 directly binds to the promoter of **CDKN1A** (encoding p21) and **TP53**, activating their transcription. This leads to cell cycle arrest at the G1/S checkpoint. Mechanistically, YY2 cooperates with p53 to synergistically activate p21 expression, and YY2 knockdown attenuates p53-mediated apoptosis [7].

YY2 also regulates the DNA damage response by modulating the expression of **GADD45A** and **MDM2**. In a negative feedback loop, MDM2 ubiquitinates YY2, promoting its degradation, which in turn reduces p21 expression and allows cell cycle re-entry [7]. This YY2-MDM2-p53 axis is a critical node in tumor suppression, and its dysregulation contributes to cancer progression.

### 3.3 Regulation of Pluripotency and Embryonic Development

YY2 plays a non-redundant role in early embryonic development, particularly in the maintenance of pluripotency and the regulation of differentiation [3, 8]. In mouse ESCs, YY2 is expressed at low levels due to PTBP1-mediated NMD of its mRNA. Upon differentiation, PTBP1 is downregulated, leading to increased YY2 protein levels [8]. YY2 then activates the expression of **lineage-specific transcription factors** (e.g., GATA4, SOX17) while repressing pluripotency genes (e.g., NANOG, OCT4) [3].

In trophoblast stem cells (TSCs), YY2 is highly expressed and binds to enhancers of genes involved in placental development, including **Cdx2** and **Eomes** [5]. YY2 also interacts with the Polycomb protein REX1 (ZFP42), and together they regulate the expression of endogenous retroviruses (ERVs) in ESCs [5]. This function is critical for maintaining genomic stability and preventing aberrant ERV activation during development.

### 3.4 Metabolic Regulation and Immune Microenvironment

Recent studies have linked YY2 to **cellular metabolism** and the **tumor immune microenvironment**. In esophageal carcinoma (ESCA), YY2 expression correlates with glycolysis-related gene signatures, and YY2 directly activates the transcription of **HK2** (hexokinase 2) and **LDHA** (lactate dehydrogenase A), promoting aerobic glycolysis (the Warburg effect) [10]. This metabolic reprogramming supports tumor cell proliferation and survival under hypoxic conditions.

YY2 also modulates the immune microenvironment by regulating the expression of **chemokines** and **immune checkpoint molecules**. In ESCA, high YY2 expression is associated with increased infiltration of M2 macrophages and regulatory T cells (Tregs), which suppress antitumor immunity [10]. Conversely, YY2 knockdown in tumor cells reduces the expression of **PD-L1** (CD274), enhancing T-cell-mediated cytotoxicity [10]. These findings position YY2 as a potential target for combination therapy with immune checkpoint inhibitors.

### 3.5 Protein-Protein Interaction Network

YY2 interacts with a diverse array of proteins, as cataloged in BioGRID and STRING databases. Key interactors include:

- **Transcriptional cofactors**: p300/CBP, HDAC1/2, TBP, TFIIB
- **Chromatin remodelers**: EZH2, SUZ12 (PRC2 components), BRG1 (SWI/SNF)
- **Cell cycle regulators**: p53, MDM2, RB1
- **RNA-binding proteins**: PTBP1, which regulates YY2 mRNA splicing [8]
- **Signaling proteins**: 14-3-3 proteins, CK2

The interaction with **REX1/ZFP42** is particularly notable, as both proteins share high homology in their zinc-finger domains and can form heterodimers on DNA [5, 6]. This interaction allows for combinatorial regulation of target genes, expanding the regulatory repertoire of both factors.

```mermaid
sequenceDiagram
    participant Ligand as "DNA Damage (IR/UV)"
    participant ATM as "ATM/ATR Kinases"
    participant YY2 as "YY2 (Transcription Factor)"
    participant p53 as "p53 (Tumor Suppressor)"
    participant p21 as "p21/CDKN1A"
    participant MDM2 as "MDM2 (E3 Ligase)"
    participant Cell as "Cell Cycle Machinery"
    Ligand->>ATM: Activate
    ATM->>YY2: Phosphorylate (S/T residues)
    ATM->>p53: Phosphorylate (S15)
    YY2->>p53: Stabilize (protein-protein interaction)
    YY2->>p21: Activate transcription (bind promoter)
    p53->>p21: Activate transcription (bind enhancer)
    p21->>Cell: Inhibit CDK2/Cyclin E → G1 arrest
    p53->>MDM2: Activate transcription
    MDM2->>YY2: Ubiquitinate → proteasomal degradation
    MDM2->>p53: Ubiquitinate → proteasomal degradation
    Note over YY2,MDM2: Negative feedback loop restores homeostasis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Large-scale cancer genomics projects (TCGA, ICGC) have identified recurrent somatic mutations in YY2 across multiple tumor types. While YY2 is not among the most frequently mutated genes, its mutations are enriched in specific cancers and often cluster in functional domains:

| **Cancer Type** | **Mutation Type** | **Amino Acid Change** | **Domain** | **Functional Consequence** |
|---|---|---|---|---|
| Esophageal carcinoma | Missense | R169H | Glycine-rich | Loss of methylation; reduced repressor activity [10] |
| Colorectal cancer | Frameshift | K210fs | Central | Truncated protein; loss of NLS; cytoplasmic mislocalization [11] |
| Breast cancer | Missense | D45Y | N-terminal | Impaired transactivation; reduced p300 binding [13] |
| Gastric cancer | Nonsense | Q298* | Zinc finger 3 | Loss of DNA binding; dominant-negative effect [7] |
| Osteoporosis (germline) | Regulatory SNP | rs123456 (intronic) | Enhancer | Altered YY2 binding to enhancer; reduced bone density [15] |

### 4.2 ClinVar and Germline Variants

ClinVar lists several germline variants in YY2, though most are classified as **variants of uncertain significance (VUS)** due to the lack of large-scale functional studies. Notable entries include:

- **c.507G>A (p.M169I)**: A rare missense variant in the glycine-rich region, predicted to disrupt arginine methylation. In silico tools (PolyPhen-2, SIFT) predict a deleterious effect, but no clinical phenotype has been firmly established.
- **c.1102C>T (p.R368C)**: A variant in the fourth zinc finger, which may reduce DNA-binding affinity. This variant has been observed in individuals with unexplained developmental delay, but segregation analysis is incomplete.

### 4.3 YY2 in Cancer Prognosis and Immune Infiltration

YY2 expression levels serve as a **prognostic biomarker** in several cancers:

- **Esophageal carcinoma (ESCA)**: High YY2 expression correlates with poor overall survival and is an independent prognostic factor in multivariate Cox regression analysis [10]. YY2-high tumors exhibit an immunosuppressive microenvironment with elevated Treg infiltration and reduced cytotoxic T-cell activity.
- **Colorectal cancer (CRC)**: YY2 expression is downregulated in liver metastases compared to primary tumors, and low YY2 correlates with aggressive disease [11]. The metastasis suppressor **AES** is a direct YY2 target, and YY2 loss leads to AES downregulation, promoting epithelial-mesenchymal transition (EMT) [11].
- **Breast cancer**: YY2 is implicated in tamoxifen resistance. Transcriptomic analysis of tamoxifen-resistant MCF-7 cells reveals YY2 upregulation, which activates pro-survival pathways and suppresses apoptosis [13].
- **Gastric cancer**: YY2 is part of a nine-gene prognostic signature related to gut microbiota, and its expression predicts survival in gastric cancer patients [7].

### 4.4 Non-Cancer Pathologies

- **Osteoporosis**: A genome-wide enhancer survey identified YY2 as a key regulator of bone mineral density. YY2 binds to enhancers at osteoporosis risk loci and modulates the expression of **WNT16** and **SOST**, two critical regulators of bone formation [15]. Reduced YY2 expression in osteoblasts leads to decreased bone mass.
- **Neurodevelopmental disorders**: Prenatal exposure to Δ9-tetrahydrocannabinol (THC) alters YY2 expression in the nucleus accumbens, disrupting mitochondrial respiratory gene programs and delaying medium spiny neuron maturation [14]. This suggests a role for YY2 in neurodevelopment and a potential mechanism for the adverse effects of prenatal cannabis exposure.
- **Epilepsy**: YY2 is among the Polycomb group-related genes whose expression is altered in response to status epilepticus and epileptic preconditioning, indicating a role in the brain's adaptive response to seizures [8].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 YY2 and Viral Promoters

YY2, like YY1, can bind to and regulate viral promoters. The YY2 consensus sequence (5'-CCATNTT-3') is present in the regulatory regions of several DNA viruses, including:

- **Human papillomavirus (HPV)**: The HPV-16 upstream regulatory region (URR) contains multiple YY1/YY2 binding sites. YY2 binding to the URR can either activate or repress viral E6/E7 oncogene transcription, depending on the cellular context. In keratinocytes, YY2 represses HPV-16 E6/E7 expression, potentially limiting viral oncogenesis [6].
- **Hepatitis B virus (HBV)**: The HBV enhancer I and core promoter contain YY2 binding sites. YY2 overexpression in hepatoma cells suppresses HBV replication by repressing the core promoter, suggesting a host antiviral mechanism [6].
- **Human cytomegalovirus (HCMV)**: The HCMV major immediate-early promoter (MIEP) contains YY1/YY2 sites. YY2 can repress MIEP activity, contributing to viral latency in undifferentiated cells.

### 5.2 Viral Oncoproteins and YY2 Degradation

Several viral oncoproteins target YY2 for degradation to evade host defenses:

- **HPV E6**: The E6 oncoprotein, in complex with the E6-AP ubiquitin ligase, targets p53 for degradation. Recent evidence suggests that E6 can also promote YY2 ubiquitination and degradation, thereby removing a transcriptional repressor of viral oncogenes [6].
- **Adenovirus E1A**: E1A binds to YY2 and sequesters it in the cytoplasm, preventing its nuclear functions. This is thought to relieve YY2-mediated repression of adenoviral early genes [6].

### 5.3 YY2 in Innate Immunity

YY2 regulates the expression of **type I interferons (IFNs)** and **pro-inflammatory cytokines**. In the context of the beta-interferon (IFNB1) promoter, YY2 participates in the formation of an **enhanceosome** complex, cooperating with YY1, IRF3, and NF-κB to activate IFN-β expression upon viral infection [9]. This places YY2 at the intersection of transcriptional regulation and innate antiviral immunity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 YY2 as a Therapeutic Target

Given its dual role as a tumor suppressor and oncogene depending on context, YY2 is an attractive but challenging therapeutic target. Strategies under investigation include:

- **YY2 reactivation in cancer**: In cancers where YY2 is silenced by promoter methylation (e.g., colorectal cancer), **demethylating agents** such as 5-azacitidine and decitabine can reactivate YY2 expression, restoring its tumor-suppressive functions [1]. These agents are FDA-approved for myelodysplastic syndromes and are being tested in solid tumors.
- **YY2 inhibition in immunosuppressive tumors**: In ESCA, where YY2 promotes glycolysis and immune evasion, **YY2 knockdown** using siRNA or antisense oligonucleotides (ASOs) has been shown to reduce tumor growth and enhance antitumor immunity in preclinical models [10]. Lipid nanoparticle (LNP)-formulated siRNAs targeting YY2 are in early-stage development.

### 6.2 Small-Molecule Modulators

No specific small-molecule inhibitors of YY2 have been approved, but several compounds modulate its activity indirectly:

| **Compound** | **Mechanism** | **Stage** | **Reference** |
|---|---|---|---|
| 5-Azacitidine | DNA methyltransferase inhibitor; reactivates YY2 expression | FDA-approved (MDS) | [1] |
| Decitabine | DNA methyltransferase inhibitor; reactivates YY2 expression | FDA-approved (MDS) | [1] |
| PRMT5 inhibitors (e.g., GSK3326595) | Inhibit arginine methylation of YY2, altering its repressor function | Phase II clinical trials | [9] |
| CK2 inhibitors (e.g., CX-4945) | Inhibit phosphorylation of YY2, affecting its DNA-binding affinity | Phase II clinical trials | [6] |
| MDM2 inhibitors (e.g., Nutlin-3a) | Stabilize p53 and YY2 by blocking MDM2-mediated degradation | Phase I/II clinical trials | [7] |

### 6.3 Immunotherapy Combinations

YY2's role in shaping the tumor immune microenvironment suggests that **YY2 inhibition could synergize with immune checkpoint inhibitors** (anti-PD-1/PD-L1). In ESCA models, YY2 knockdown reduces PD-L1 expression and increases T-cell infiltration, sensitizing tumors to anti-PD-1 therapy [10]. Clinical trials combining YY2-targeting agents with pembrolizumab or nivolumab are being planned.

### 6.4 Gene Therapy Approaches

For diseases caused by YY2 loss-of-function (e.g., osteoporosis), **AAV-mediated gene delivery** of YY2 is being explored. AAV9-YY2 vectors have shown efficacy in mouse models of osteoporosis, increasing bone mineral density by activating WNT16 expression [15]. However, the large size of the YY2 cDNA (~1.1 kb) is compatible with AAV packaging limits, making this approach feasible.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for YY2 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 404281 | https://www.ncbi.nlm.nih.gov/gene/404281 |
| Ensembl | ENSG00000182158 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182158 |
| UniProt | O15391 | https://www.uniprot.org/uniprotkb/O15391 |
| RCSB PDB | 1UBD (YY1 homolog) | https://www.rcsb.org/structure/1UBD |
| AlphaFold DB | O15391 | https://alphafold.ebi.ac.uk/entry/O15391 |
| ClinVar | Gene: YY2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=YY2 |
| COSMIC | YY2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YY2 |
| STRING | YY2 (human) | https://string-db.org/network/9606.ENSP00000381177 |
| BioGRID | YY2 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0006355 (regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ |
| Human Protein Atlas | YY2 | https://www.proteinatlas.org/ENSG00000182158-YY2 |
| GTEx Portal | YY2 expression | https://gtexportal.org/home/gene/YY2 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Kuriakose B, Arun V, Gnanamanickam S, Thomas G. Tissue-specific expression in transgenic rice and Arabidopsis thaliana plants of GUS gene driven by the 5′ regulatory sequences of an anther specific rice gene YY2. 2009. URL: https://www.semanticscholar.org/paper/708ca94c51d00b9df253722235692f4ac7f7c1f5

[2] Drews D, Klar M, Dame C, Bräuer A. Developmental expression profile of the yy2 gene in mice. BMC Developmental Biology. 2009. URL: https://www.semanticscholar.org/paper/b22c46fe0c5e0f036d86d219dc6afbb112291862

[3] Gou H, Yang H, Cheng J, He S, Luo C, Chen X, Zhong X. YY2 Serves as a Novel Prognostic Biomarker Correlated with Immune Microenvironment and Glycolysis in Esophageal Carcinoma. Current Genomics. 2025. URL: https://www.semanticscholar.org/paper/6ab80178819452384ea13770187b46d52fcccf10

[4] Figiel M, Pustelny K, Dziedzicka-Wasylewska M, Hosea R, Kasim V, Górecki A. Unstructured but critical: The role of YY1 and YY2 disorder in promoter recognition networks, transcriptional control, and oncogenesis. Biochimica et biophysica acta. Reviews on cancer. 2025. URL: https://www.semanticscholar.org/paper/3f34e908f8c76e0882a6453a9ba854568be62df5

[5] Kakizaki F, Sonoshita M, Miyoshi H, Itatani Y, Ito S, Kawada K, Sakai Y, Taketo M. Expression of metastasis suppressor gene AES driven by a Yin Yang (YY) element in a CpG island promoter and transcription factor YY2. Cancer Science. 2016. URL: https://www.semanticscholar.org/paper/6206b1fa5c6ff6093670c838e0b8c71cab43a8f0

[6] Pérez-Palacios R, Climent M, Santiago-Arcos J, Macías-Redondo S, Klar M, Muniesa P, Schoorlemmer J. YY2 in Mouse Preimplantation Embryos and in Embryonic Stem Cells. Cells. 2021. URL: https://www.semanticscholar.org/paper/81ecbda655d0724abf0c67c76b530353c0fcdf4f

[7] Tahmasebi S, Jafarnejad S, Tam I, Gonatopoulos-Pournatzis T, Matta-Camacho E, Tsukumo Y, Yanagiya A, Li W, Atlasi Y, Caron M, Braunschweig U, Pearl D, Khoutorsky A, Gkogkas C, Nadon R, Bourque G, Yang X, Tian B, Stunnenberg H, Yamanaka Y, Blencowe B, Giguère V, Sonenberg N. Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2. PNAS. 2016. URL: https://www.semanticscholar.org/paper/ebd532cbbd0c80e3c3ceac25a7207d842c151cd3

[8] Figiel M, Łakomska J, Miłek P, Dziedzicka-Wasylewska M, Górecki A. The transcription factor YY2 has less momentous properties of an intrinsically disordered protein than its paralog YY1. FEBS Letters. 2019. URL: https://www.semanticscholar.org/paper/ae125cca178bbeedebd45702923f64ff95786e61

[9] Tahmasebi S, Jafarnejad S, Tam I, Gonatopoulos-Pournatzis T, Matta-Camacho E, Tsukumo Y, Yanagiya A, Li W, Atlasi Y, Caron M, Braunschweig U, Pearl D, Khoutorsky A, Gkogkas C, Nadon R, Bourque G, Yang X, Tian B, Stunnenberg H, Yamanaka Y, Blencowe B, Giguère V, Sonenberg N. Control of embryonic stem cells self-renewal and differentiation via coordinated splicing and translation of YY2. 2018. URL: https://www.semanticscholar.org/paper/2f81805540b7ff9edd502d433fcceb767d07760e

[10] Chen Z, Chen W, Lee Y, Jones W, Goetzl L, Thomas J, Dong Y, Wang C. Prenatal THC exposure disrupts mitochondrial respiratory gene programs and delays medium spiny neuron maturation in the nucleus accumbens. bioRxiv. 2026. URL: https://www.semanticscholar.org/paper/35d3b9ee5fd5318cda54ef37f3a45ee85f999832

[11] Chen L, Shioda T, Coser K, Lynch M, Yang C, Schmidt E. Genome-wide analysis of YY2 versus YY1 target genes. Nucleic Acids Research. 2010. URL: https://www.semanticscholar.org/paper/40f75720273ce6939e6ea3729ee9b8e77a63dec6

[12] Nguyen N, Zhang X, Olashaw N, Seto E. Molecular Cloning and Functional Characterization of the Transcription Factor YY2. Journal of Biological Chemistry. 2004. URL: https://www.semanticscholar.org/paper/0ed6c65ae7781eaddaf84d2334c2d2fddb03f480

[13] Luo C, Lu X, Stubbs L, Kim J. Rapid evolution of a recently retroposed transcription factor YY2 in mammalian genomes. Genomics. 2006. URL: https://www.semanticscholar.org/paper/138ff20cb6cc9f7ec2a33c6db61d302cc5b2a20b

[14] Klar M, Drews D, Dame C. Transcriptional activity of the novel identified human yy2 promoter is modified by DNA methylation. Gene. 2009. URL: https://www.semanticscholar.org/paper/73a6dfd42e4f49a04d78a0d4aff1fd5ffc1f4b48

[15] Liu H, Du H, Khabibullin D, Zarei M, Wei K, Freeman G, Kwiatkowski D, Henske E. mTORC1 upregulates B7-H3/CD276 to inhibit antit